PMID: 15988121Jul 1, 2005

Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release

Drug Metabolism and Pharmacokinetics
Akiko Matsui-SakataYasufumi Sawada


We aimed to analyze the risks of extrapyramidal symptoms (EPS) induced by typical and atypical antipsychotic drugs using a common pharmacokinetic-pharmacodynamic (PK-PD) model based on the receptor occupancy. We collected the data for EPS induced by atypical antipsychotics, risperidone, olanzapine and quetiapine, and a typical antipsychotic, haloperidol from literature and analyzed the following five indices of EPS, the ratio of patients obliged to take anticholinergic medication, the occurrence rates of plural extrapyramidal symptoms (more than one of tremor, dystonia, hypokinesia, akathisia, extrapyramidal syndrome, etc.), parkinsonism, akathisia, and extrapyramidal syndrome. We tested two models, i.e., a model incorporating endogenous dopamine release owing to 5-HT2A receptor inhibition and a model not considering the endogenous dopamine release, and used them to examine the relationship between the D2 receptor occupancy of endogenous dopamine and the extent of drug-induced EPS. The model incorporating endogenous dopamine release better described the relationship between the mean D2 receptor occupancy of endogenous dopamine and the extent of EPS than the other model, as assessed by the final sum of squares of residuals (fina...Continue Reading


Dec 1, 1987·Journal of Clinical Psychopharmacology·J ClaghornG Klerman
Oct 1, 1987·Pharmaceutical Research·M G ChocJ Volavka
Jan 1, 1984·European Archives of Psychiatry and Neurological Sciences·P LinkowskiJ Mendlewicz
May 1, 1994·Psychopharmacology·G MannensJ Heykants
Feb 1, 1995·Journal of Clinical Psychopharmacology·M Huttunen
Mar 1, 1994·Neuropharmacology·F G Boess, I L Martin
May 1, 1996·The British Journal of Psychiatry. Supplement·S R HirschL A Arvanitis
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C M BeasleyS H Hamilton
Mar 1, 1996·Psychopharmacology·C M BeasleyS H Hamilton
Feb 1, 1997·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Y SawadaTatsuji Iga
May 1, 1997·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·C M BeasleyJ N Beuzen
Nov 14, 1997·Acta Psychiatrica Scandinavica·J Peuskens, C G Link
Dec 2, 1998·British Journal of Clinical Pharmacology·G SchaberU Breyer-Pfaff
Apr 3, 1999·British Journal of Pharmacology·C ReavillT P Blackburn
Apr 8, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·D G DanielM Lakshminarayanan
Jun 18, 1999·The Journal of Clinical Psychiatry·D Naber
Jan 11, 2000·Clinical Pharmacokinetics·S Kudo, T Ishizaki
Jan 14, 2000·European Journal of Endocrinology·A E MinettiA Sartorio
Mar 21, 2000·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·M Laruelle
Apr 18, 2001·The Journal of Clinical Investigation·E Keshet
Aug 19, 2003·Journal of the American Academy of Child and Adolescent Psychiatry·Norman E Alessi


Feb 20, 2008·Palliative & Supportive Care·Yu SunakawaYasutsuna Sasaki
Aug 24, 2007·Clinical Pharmacokinetics·Jasper Dingemanse, Silke Appel-Dingemanse
Sep 29, 2006·Proceedings of the National Academy of Sciences of the United States of America·Samarjit BhattacharyyaMitradas M Panicker
Apr 2, 2013·Expert Opinion on Drug Safety·José López-SendónJusto G de Yébenes
Aug 1, 2009·Expert Opinion on Drug Discovery·Gianluca NucciItalo Poggesi
Oct 19, 2006·Expert Opinion on Drug Safety·Maria A Mena, Justo G de Yébenes
Aug 31, 2010·Bioorganic & Medicinal Chemistry Letters·David A FavorKevin A Serpa
Jan 1, 2012·CPT: Pharmacometrics & Systems Pharmacology·V Pilla ReddyL E Friberg
Mar 19, 2015·Journal of Psychiatric Practice·Juan Soriano-BarcelóDavid A Kahn
Nov 9, 2016·Parkinsonism & Related Disorders·Lucy HaggstromStephen Tisch
Feb 4, 2014·Therapeutic Advances in Psychopharmacology·Marina Salviato BalbãoRegina Helena Costa Queiroz

Related Concepts

Ziprasidone hydrochloride, monohydrate
Lenticulostriate Disorders

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.